POMGNT1

Across TCGA pan-cancer cohorts, POMGNT1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated POMGNT1 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher POMGNT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated POMGNT1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, GBM, and HNSC are the cancer types where POMGNT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.927	1.000	.011	13	view →
GBM	DFS	Tertile	All	0.838	0.637	.006	11	view →
HNSC	DFS	Tertile	IV	0.588	0.831	.018	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

POMGNT1–LUAD (OS)

Open the LUAD breakdown →